secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-08-13T11:05:15+00:00
Accession:  0001193125-26-347853
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Pharmaceuticals appoints Jason O'Byrne as CFO, effective Aug 11, 2026
---------------------------------------------------------------------------

- O'Byrne previously CFO at Vir Biotechnology (2024-2026) and Caribou Biosciences (2021-2024); joins Olema from Vir.
- Compensation: $545,000 base salary, 45% target bonus, $250,000 sign-on bonus plus $100,000 at 1-year anniversary.
- Granted option for 650,000 shares under 2022 Inducement Plan, vesting over 4 years (25% at 1-year, then monthly).
- Company cites upcoming pivotal OPERA-01 data and first potential commercial launch; highlights palazestrant and OP-3136.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/0001193125-26-347853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526347853/olma-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-347853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer